Abstract:Targeted protein degradation (TPD) has emerged as a prominent and vital strategy for therapeutic intervention of cancers and other diseases. One such approach involves the exploration of proteolysis targeting chimeras (PROTACs) for the selective elimination of disease-causing proteins through the innate ubiquitin-proteasome pathway. Due to the unprecedented achievements of various PROTAC molecules in clinical trials, researchers have moved towards other physiological protein degradation approaches for the targeted degradation of abnormal proteins, including lysosome-targeting chimeras (LYTACs), autophagy-targeting chimeras (AUTACs), autophagosome-tethering compounds (ATTECs), molecular glue degraders, and other derivatives for their precise mode of action. Despite numerous advantages, these molecules face challenges in solubility, permeability, bioavailability, and potential off-target or on-target off-tissue effects. Thus, an urgent need arises to direct the action of these degrader molecules specifically against cancer cells, leaving the proteins of non-cancerous cells intact. Recent advancements in TPD have led to innovative delivery methods that ensure the degraders are delivered in a cell- or tissue-specific manner to achieve cell/tissue-selective degradation of target proteins. Such receptor-specific active delivery or nano-based passive delivery of the PROTACs could be achieved by conjugating them with targeting ligands (antibodies, aptamers, peptides, or small molecule ligands) or nano-based carriers. These techniques help to achieve precise delivery of PROTAC payloads to the target sites. Notably, the successful entry of a Degrader Antibody Conjugate (DAC), ORM-5029, into a phase 1 clinical trial underscores the therapeutic potential of these conjugates, including LYTAC-antibody conjugates (LACs) and aptamer-based targeted protein degraders. Further, using bispecific antibody-based degraders (AbTACs) and delivering the PROTAC pre-fused with E3 ligases provides a solution for cell type-specific protein degradation. Here, we highlighted the current advancements and challenges associated with developing new tumour-specific protein degrader approaches and summarized their potential as single agents or combination therapeutics for cancer.

Development of natural product-based targeted protein degraders as anticancer agents

Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies Against Cancer

Targeted protein degrader development for cancer: advances, challenges, and opportunities

Advancing targeted protein degradation for cancer therapy

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Recent advances in targeted protein degraders as potential therapeutic agents

Powering up targeted protein degradation through active and passive tumour-targeting strategies: Current and future scopes

Targeted protein degradation in drug development: Recent advances and future challenges

Targeted protein degradation: advances in drug discovery and clinical practice

Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance

Hydrophobic tag-based protein degradation: Development, opportunity and challenge

Novel approaches to targeted protein degradation technologies in drug discovery

Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques

Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Targeted protein degradation: mechanisms, strategies and application

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Advancing targeted protein degradation for metabolic diseases therapy

PROTAC targeted protein degraders: the past is prologue

Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies